Skip to main content
Back
Watch Compare

Pelthos Therapeutics Inc.

Data quality: 100%
PTHS
NYSE Manufacturing Chemicals
$22.50
▼ $0.40 (-1.75%)
Mkt Cap: 75.50 M
Price
$22.50
Mkt Cap
75.50 M
Day Range
$22.50 — $22.99
52-Week Range
$9.00 — $54.29
Volume
3,086
Open $22.99
50D / 200D Avg
$23.03
2.28% below
50D / 200D Avg
$25.04
10.14% below

Quick Summary

Key Takeaways

Negative free cash flow of -22.69 M
Capital efficient — spends only 0.59% of revenue on capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-167.39%
Below sector avg (-53.41%)
ROIC-53.84%
Net Margin-257.93%
Op. Margin-193.09%

Safety

Debt / Equity
N/A
Current Ratio2.01
Interest Coverage-10.77

Valuation

PE (TTM)
-1.74
Below sector avg (-1.48)
P/B Ratio1.30
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -1.7 -1.5
P/B 1.3 1.6
ROE % -167.4 -53.4
Net Margin % -257.9 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 16.80 M Net Income (TTM) -43.32 M
ROE -167.39% ROA -68.08%
Gross Margin N/A Operating Margin -193.09%
Net Margin -257.93% Free Cash Flow (TTM) -22.69 M
ROIC -53.84% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.01
Interest Coverage -10.77 Asset Turnover 0.26
Working Capital 24.99 M Tangible Book Value -4.89 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.74 Forward P/E N/A
P/B Ratio 1.30 P/S Ratio 4.50
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -30.05%
Market Cap 75.50 M Enterprise Value 61.30 M
Per Share
EPS (Diluted TTM) -23.04 Revenue / Share 5.01
FCF / Share -6.76 OCF / Share -6.73
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.59% FCF Conversion 52.38%
SBC-Adj. FCF -26.64 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 16.80 M — —
Net Income -43.32 M -7.96 M -7.38 M
EPS (Diluted) -23.04 -1.43 —
Gross Profit — — —
Operating Income -32.43 M -7.57 M -6.86 M
EBITDA — — —
R&D Expenses 1.23 M 1.18 M 2.58 M
SG&A Expenses 42.45 M — —
D&A — — —
Interest Expense 3.01 M 581,055.0 14,370.0
Income Tax -7.39 M — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 130.40 M 1.37 M 96,391.0
Total Liabilities 91.52 M 4.08 M 6.54 M
Shareholders' Equity 38.88 M -2.71 M -6.44 M
Total Debt — — —
Cash & Equivalents 17.97 M — 100,000.0
Current Assets 53.41 M 1.37 M 96,391.0
Current Liabilities 25.99 M 4.08 M 6.54 M